Income statement
GBP
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 46M | 42M | 36M | 31M | 31M |
| Gross Profit | 38M | 34M | 29M | 22M | 25M |
| Operating Income | 8M | 7M | 5M | 4M | 5M |
| EBITDA | 11M | 10M | 8M | 5M | 6M |
| Net Income | 7M | 6M | 4M | -1M | 4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$5.53
+0.00% today
1Y Change
+4.54%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 255 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tristel PLC (TSNLF) is a Healthcare stock with a market cap of $190.00M and listed on OTC. The stock last traded around $5.53 and up 4.5% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +10.8%, EPS growth of 0.0%, a dividend yield of 3.5%. What stands out right now is revenue +10.8%, EPS 0.0%, free cash flow +8.7% with operating margin 19.7% and ROIC 19.7%. The dividend matters to the case here, with a current yield around 3.5%. Valuation is more restrained than many high-expectation growth names at P/E 24.6 and price/sales 3.9. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines TSNLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TSNLF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TSNLF Max Drawdown
-16.67%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TSNLF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$31.0M
-0.4% YoY
FY Net Income
$3.7M
+392.7% YoY
Free Cash Flow
$4.7M
+8.3% YoY
Revenue Growth
+10.8%
EPS Growth
+0.0%
Gross Margin
78.7%
Net Margin
15.9%
Income statement
GBP
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 46M | 42M | 36M | 31M | 31M |
| Gross Profit | 38M | 34M | 29M | 22M | 25M |
| Operating Income | 8M | 7M | 5M | 4M | 5M |
| EBITDA | 11M | 10M | 8M | 5M | 6M |
| Net Income | 7M | 6M | 4M | -1M | 4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
GBP
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 9M | 6M | 7M | 9M | 8M |
| Total Assets | 45M | 44M | 41M | 39M | 40M |
| Total Liabilities | 12M | 12M | 11M | 10M | 10M |
| Shareholder Equity | 33M | 32M | 31M | 29M | 30M |
| Total Debt | 6M | 6M | 5M | 6M | 6M |
| Net Debt | -3M | -275K | -2M | -3M | -2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6M
+16.7% YoY
Capital Expenditures
2M
-46.9% YoY
Free Cash Flow
5M
+8.3% YoY
Key ratios
Gross Margin
78.7%
Operating Margin
19.7%
Net Margin
15.9%
ROE
23.6%
Debt / Equity
0.17x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.